---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Bone-targeted agents"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Bone-targeted agents. Topics: FDA-approved indications, Denosumab versus zoledronic acid in castration-resistant disease with bone metastases, Zoledronic acid versus placebo in metastatic prostate cancer, Osteonecrosis of the jaw and hypocalcemia, and 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/bone-targeted-agents"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Bone-targeted agents

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 Bone-targeted Agents

<a id="topic-2.2.2.1.9-1"></a>

### FDA-approved indications

> “Xgeva is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.”

Source: [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)

> “Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.”
> “Prostate cancer should have progressed after treatment with at least one hormonal therapy.”

Source: [Zometa prescribing information (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021223s041lbl.pdf)

<a id="topic-2.2.2.1.9-2"></a>

### Denosumab versus zoledronic acid in castration-resistant disease with bone metastases

> “Median time to first on-study skeletal-related event was 20·7 months (95% CI 18·8–24·9) with denosumab compared with 17·1 months (15·0–19·4) with zoledronic acid (hazard ratio 0·82, 95% CI 0·71–0·95; p=0·0002 for non-inferiority; p=0·008 for superiority).”
> “More events of hypocalcaemia occurred in the denosumab group (121 [13%]) than in the zoledronic acid group (55 [6%]; p<0·0001).”
> “Osteonecrosis of the jaw occurred infrequently (22 [2%] vs 12 [1%]; p=0·09).”

Source: [Fizazi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3090685/)

> “Overall survival and progression-free survival were similar between arms in all three trials.”

Source: [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)

<a id="topic-2.2.2.1.9-3"></a>

### Zoledronic acid versus placebo in metastatic prostate cancer

| Study | Patients with a skeletal-related event, zoledronic acid 4 mg | Patients with a skeletal-related event, placebo | Median days to first skeletal-related event, zoledronic acid 4 mg | Median days to first skeletal-related event, placebo | Hazard ratio for first skeletal-related event (95% CI) |
| --- | --- | --- | --- | --- | --- |
| Prostate cancer study | “33%” | “44%” | “Not Reached” | “321” | “0.67 (0.49, 0.91)” |

Source: [Zometa prescribing information (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021223s041lbl.pdf)

> “No survival benefit has been seen in any prospective trial with bisphosphonates.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.9-4"></a>

### Osteonecrosis of the jaw and hypocalcemia

> “In the primary treatment phases of Studies 20050136, 20050244, and 20050103, ONJ was confirmed in 1.8% of patients in the Xgeva group (median exposure of 12.0 months; range: 0.1-41) and 1.3% of patients in the zoledronic acid group.”

Source: [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)

> “The potential toxicity (e.g. osteonecrosis of the jaw, hypocalcaemia) of these drugs must always be kept in mind (5–8.2% in M0 CRPC and mCRPC, respectively)”
> “Daily calcium (> 500 mg) and vitamin D (> 400 IU equivalent) are recommended in all patients, except in case of hypercalcaemia”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.9-5"></a>

### Bone protection during ARPI and radium-223 treatment

> “For patients who received bone protecting agent (BPA) therapy, after it became mandatory on the trial, fracture rates significantly decreased in both study arms one-year fractures decreased from 15.6% to 2.6% with a BPA in patients receiving enzalutamide monotherapy.”
> “This underscores the high risk of fracture in patients with mCRPC and the necessity of complying with guidelines regarding BPA administration in the ARPI era”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

Additional sources: [Saad et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12359855/); [Saylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31990618/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
